BC Innovations | Oct 28, 2019
Distillery Therapeutics

Prolactin inhibition could treat MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Inhibition of PRL or ZBTB20, a transcription factor that promotes PRL expression, could treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CSF levels...
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BioCentury | Apr 19, 2019
Finance

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
BC Week In Review | Apr 11, 2019
Company News

Hope Medicine in-licenses Bayer’s BAY 1158061

Hope Medicine gained exclusive, worldwide rights from Bayer to develop and commercialize BAY 1158061 to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc. (Beijing,...
BC Extra | Apr 10, 2019
Financial News

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors. Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round...
BC Week In Review | Jul 25, 2016
Clinical News

XOMA 213: Phase II started

Xoma began an open-label, Spanish Phase II proof-of-concept (POC) trial to evaluate 2 dose levels of IV XOMA 213 in up to 35 women who wish to suppress lactation immediately after delivery. Xoma said it...
BC Extra | Sep 17, 2015
Top Story

Phase III schizophrenia data lift Intra-Cellular to record high

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) climbed $22.68 (87%) to an all-time high close of $48.79 on Wednesday after the 60 mg dose of ITI-007 met the primary endpoint in a Phase III trial to treat schizophrenia....
BioCentury | Feb 16, 2015
Product Development

The straight dopa

Laboratoires Pierre Fabre S.A. thinks the dopamine D3 receptor hypothesis of schizophrenia hasn't been fully tested yet because the compounds that failed earlier trials didn't engage enough of the receptors. To avoid that problem, the...
BC Innovations | Aug 21, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Prolactin (PRL); PRL receptor (PRLR) In vitro and mouse studies suggest increasing PRL signaling could help prevent hepatocellular carcinoma (HCC). In human and...
BC Innovations | Jul 24, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; thrombosis Plasminogen activator inhibitor 1 (SERPINE1; PAI1) In vitro and mouse studies suggest enhancing the interaction of PAI1 with the N-terminal region of prolactin...
Items per page:
1 - 10 of 60